news

Midatech appoints Nick Robbins-Cherry as Finance Director

Posted: 2 July 2014 | | No comments yet

Midatech Ltd. is pleased to announce that Nick Robbins-Cherry has been appointed as Finance Director, further strengthening the Company’s senior management team…

Midatech

Midatech Ltd., a global leader in the design, synthesis and manufacture of nanomedicines based on its unique gold glycan coated nanoparticle (GNP) technology, is pleased to announce that Nick Robbins-Cherry has been appointed as Finance Director (FD), further strengthening the Company’s senior management team.

Nick Robbins-Cherry MBA ACA is a chartered accountant with over 15 years of experience in senior commercial and finance roles and a proven track record in mergers and acquisitions (M&A).

He joins Midatech from The Marketing Practice, one of the UK’s leading business-to-business marketing agencies, where he acted as Finance and Commercial Director since January 2013. Prior to that, Nick spent five years at CACI, the UK subsidiary of CACI International Inc., the NYSE quoted provider of marketing solutions and IT systems, as M&A Manager and then Finance Director where he had overall responsibility for M&A activity.

Nick joined CACI from Invocom, a provider of technical consultancy services to the telecommunications industry, where he held the position of Finance Director from 2001 until the business was successfully acquired by CACI in January 2008. Nick has also held senior financial positions at LifeGard Technologies, Janssen-Cilag and ICI.

Commenting on the appointment, Dr Jim Phillips, CEO of Midatech, said: “I am delighted to welcome Nick Robbins-Cherry to the Company as our new Finance Director. Nick’s experience in senior commercial and finance roles and his track record of M&A will prove invaluable to Midatech as we look to expand the Company and commercialise novel therapeutics based on our gold nanoparticle technology.”

Nick Robbins-Cherry added: “I am excited to be joining Midatech and to have the opportunity to help drive forward the commercialisation of its game-changing GNP technology. I have been hugely impressed by the potential of this technology for the targeted delivery of therapeutics to tumour cells and for the treatment of diabetes and I am confident that Midatech has the management team in place to deliver significant growth and value in the coming years.”